Streptomycin sulfate is not currently used widely in treating Ménière's disease, primarily because ototoxic effects were demonstrated when the drug was administered in large doses in the treatmen of tuberculosis. Although great care is necessary in selecting patients, there is evidence that, with regard to the human cochlea, the toxic and therapeutic ranges do not overlap.
In 1957, eight patients with Ménière's disease, treated with streptomycin sulfate to the point of gross ataxia, were all free from vertiginous attacks and none had suffered a loss of hearing 14 to 52 months following therapy.1 Moreover, none complained of ataxia. Four of the eight patients were recently studied, nine or more years after treatment.2 None had experienced a return of Ménière's disease. In four of the five diseased ears (one patient had bilateral disease), hearing had improved significantly, and in one it was unchanged. In the unaffected ears hearing was
STREPTOMYCIN IN MÉNIÈRE'S DISEASE. JAMA. 1967;199(10):752–753. doi:10.1001/jama.1967.03120100114029
Customize your JAMA Network experience by selecting one or more topics from the list below.